Want to see DRTS full AI Analyst Report?
DRTS Stock Chart & Stats
$14.96
-$0.12(-0.96%)
At close: 4:00 PM EDT
$14.96
-$0.12(-0.96%)
Day’s Range― - ―
52-Week Range$3.43 - $15.79
Previous CloseN/A
Volume333.05K
Average Volume (3M)465.21K
Market Cap
$1.14B
Enterprise Value$1.05B
Total Cash (Recent Filing)$100.64M
Total Debt (Recent Filing)$15.15M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 24, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding92,478,160
10 Day Avg. Volume478,641
30 Day Avg. Volume465,214
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)5.17
Price to Sales (P/S)0.00
P/FCF Ratio-12.18
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.41
Forecast
1Y Price Target
$18.00Price Target Upside20.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.88
Revenue Forecast (FY)$1.13M
Bulls Say, Bears Say
Bulls Say
Expanded Clinical DevelopmentThe FDA-approved REGAIN expansion increases the amount and relevance of clinical evidence Alpha Tau can generate in recurrent glioblastoma. Broader eligibility, progression-free survival, quality-of-life measures, and interim analysis support a more informative regulatory development strategy.
Pancreatic Cancer Program ProgressCompleting enrollment in a multicenter pancreatic cancer study advances Alpha DaRT from recruitment toward data maturation and potential pivotal-study planning. The expanded enrollment and international site footprint provide a broader evidence base for evaluating the treatment alongside chemotherapy.
Moderate Leverage And Positive EquityCompared with the company’s operating losses, its moderate leverage and positive equity base provide some balance-sheet resilience. This financial structure may preserve greater flexibility to fund clinical programs than a highly debt-dependent profile, although losses remain significant.
Bears Say
No Revenue And Widening LossesThe absence of reported revenue and widening net losses show that Alpha Tau has not yet converted its development programs into a commercial earnings stream. Continued expense growth without revenue could prolong profitability pressure and increase dependence on future financing.
Persistent Cash BurnSustained operating and free-cash-flow deficits consume resources while Alpha Tau funds clinical development. If the burn rate persists, the company may need repeated external funding, which can constrain program execution and increase financing or shareholder dilution risk.
Unapproved Development-stage TechnologyAlpha DaRT remains dependent on successful clinical development and regulatory progress before it can become a routine commercial therapy. Until approval is achieved, the company lacks established product revenue and faces continuing execution risk across trials and submissions.
Alpha Tau News
DRTS FAQ
What was Alpha Tau’s price range in the past 12 months?
Alpha Tau lowest stock price was $3.43 and its highest was $15.79 in the past 12 months.
What is Alpha Tau’s market cap?
Alpha Tau’s market cap is $1.14B.
When is Alpha Tau’s upcoming earnings report date?
Alpha Tau’s upcoming earnings report date is Nov 24, 2026 which is in 36 days.
How were Alpha Tau’s earnings last quarter?
Alpha Tau released its earnings results on Aug 10, 2026. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.141 by -$0.359.
Is Alpha Tau overvalued?
According to Wall Street analysts Alpha Tau’s price is currently Undervalued.
Does Alpha Tau pay dividends?
Alpha Tau does not currently pay dividends.
What is Alpha Tau’s EPS estimate?
Alpha Tau’s EPS estimate is -0.15.
How many shares outstanding does Alpha Tau have?
Alpha Tau has 92,478,160 shares outstanding.
What happened to Alpha Tau’s price movement after its last earnings report?
Alpha Tau reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.141. Following the earnings report the stock price went up 4.926%.
Which hedge fund is a major shareholder of Alpha Tau?
Currently, no hedge funds are holding shares in DRTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Tau Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (20.32% Upside)
$18.00 (20.32% Upside)
Blogger Sentiment
Bullish
DRTS Sentiment 88%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 15.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $291.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
215.93%
12-Months-Change
Fundamentals
Return on Equity
-138.12%
Trailing 12-Months
Asset Growth
21.00%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Alpha Tau
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
DRTS Stock 12 Month Forecast
Average Price Target
$18.00
▲(20.32% Upside)
Technical Analysis
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
0.10% Insiders
0.08% Mutual Funds
0.58% Other Institutional Investors
97.94% Public Companies and
Individual Investors